Psyence Biomedical partner produced Ibogaine Total Alkaloid extract

Psyence Biomedical (PBM) announces that its strategic partner, PsyLabs has successfully produced a GMP-aligned Ibogaine Total Alkaloid extract. The high-purity extract met all microbial safety standards for food-grade consumption, as verified by an accredited third-party laboratory. In 2024, Psyence BioMed acquired an equity stake in PsyLabs and continued that investment in 2025. This achievement reflects the impact of Psyence BioMed’s ongoing investment and collaboration, which continues to support PsyLabs’ development of scalable, compliant, and globally relevant psychedelic APIs.